COVID-19: cardiovascular societies offer guidance on RAAS inhibitors

  • American Heart Association

  • Emily Willingham, PhD
  • Clinical Essentials
L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano L'accesso ai contenuti di questo sito è riservato agli operatori del settore sanitario italiano

Takeaway

  • The presidents of 3 cardiovascular societies recommend that patients currently taking renin-angiotensin-aldosterone system (RAAS) inhibitors continue to do so.
  • For patients diagnosed with COVID-19, continuation should be considered on an individual basis, they say.

Why this matters

Key information

  • The virus that causes COVID-19 gains cell entry via the angiotensin-converting enzyme (ACE) 2 receptor.
  • ACEs are implicated in cardiovascular diseases, including hypertension and heart failure.
  • Existing cardiovascular disease is a risk factor for poor outcomes in COVID-19.
  • Some heart-related effects of the causative virus have been identified, as well.
  • RAAS inhibitors include antagonists of ACE, along with angiotensin receptor blockers.
  • Some have speculated that current therapy with these drugs might enhance infection vulnerability.
  • Results of in vitro and animal studies have been mixed.
  • In the absence of evidence, societies call for continuing RAAS-inhibitor therapy in patients without COVID-19.
  • In those who are diagnosed with COVID-19, therapy decisions should be based on individual clinical status.